5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

From a finding to a target organ

Handbook tasks I.C.2–I.C.4 close Domain I interpretation: you must evaluate clinical and anatomic pathology, produce a report a reviewer can reconstruct, and integrate in-life observations with those data into a cogent conclusion. Independent OpenExamPrep teaching in this section is the anatomic half of that loop—organ weights, gross necropsy, histopathology, peer review, recovery, and the difference between a p-value and adversity.

A finding starts as a number or a lesion. It becomes a target-organ effect only after you have compared it with concurrent controls, asked whether clinical pathology shows a matching function or leakage signal, characterized distribution and severity on the slide, and decided whether the change is adaptive or adverse, local or systemic, and reversible.

Absolute versus relative organ weights

Weigh organs with consistent trimming, promptly after exsanguination, and with paired organs handled the same way every time. Report absolute weight (grams) and weight relative to body weight. Many laboratories also report weight relative to brain weight, because brain mass is more stable when animals lose carcass weight from hypophagia.

If high-dose rats eat less and lose 12–15% body weight, liver absolute weight may be unchanged or even fall while liver/body weight rises. That ratio increase is often confounded by the smaller denominator, not proof of hepatomegaly. Brain-relative liver weight that is unchanged argues against a true liver-mass increase. Pair-fed controls sometimes separate caloric restriction from test-article hepatomegaly. Small organs (thyroid, pituitary, adrenal, ovary) have high coefficients of variation; do not over-call an 8% mean shift without histology and a dose-response.

Testes are a special case: short-term body-weight loss does not shrink testes proportionally. A drop in absolute testis weight is concerning even if testis/body weight looks “normal.” The converse—testis/body weight up because the carcass shrank—does not mean testicular hypertrophy.

Terminal body weight used in the ratio should be the same weight the protocol defines (fasted versus fed). Mixing a fasted terminal weight with a fed organ-weight historical database manufactures relative-weight “findings.”

Liver hypertrophy: adaptive versus adverse

Hepatocellular hypertrophy, often centrilobular, with increased smooth endoplasmic reticulum and xenobiotic-metabolizing enzyme induction, no degeneration or necrosis, little or no ALT/GLDH increase, preserved function, and reversal after dosing stops, is commonly interpreted as adaptive (non-adverse) when those conditions hold. The same organ-weight increase with necrosis, inflammation, fibrosis, marked leakage enzymes, canalicular failure, or failure to reverse is adverse. Hypertrophy is a morphologic description, not a verdict.

Society of Toxicologic Pathology discussions of liver-weight increases emphasize this package approach. A 10% liver-weight rise is a prompt to look, not an automatic adverse call and not an automatic adaptive call. You still need concurrent controls, chemistry, and the slide.

Severity, distribution, and INHAND nomenclature

Toxicologic pathology diagnoses carry severity (minimal, mild, moderate, marked/severe) and distribution (focal, multifocal, diffuse; centrilobular, midzonal, periportal; mucosal versus transmural). Incidence plus severity tells a different story than incidence alone. A 100% incidence of minimal focal macrophage aggregates may be background. A 40% incidence of moderate diffuse necrosis is not.

INHAND (International Harmonization of Nomenclature and Diagnostic Criteria) provides standardized diagnostic terms by organ and species. Using one agreed term (for example, “hepatocellular hypertrophy”) rather than five laboratory synonyms makes incidence tables comparable across studies and supports controlled terminology used in electronic data sets. Independent OpenExamPrep coverage treats INHAND as a nomenclature standard used in modern toxicologic pathology practice. It is not a claim of sponsorship, review, or partnership with INHAND, STP, or ABT.

Peer review

A study pathologist performs the primary evaluation and signs the pathology report. Peer review by a second pathologist—often on all controls and high-dose animals, all potential target organs, and, in carcinogenicity studies, all neoplasms—documents agreement or resolved differences. Unresolved issues may go to a pathology working group (PWG). Peer review is quality control for diagnostic consistency. It is not a second Study Director, and it does not replace the Quality Assurance Unit.

Record who reviewed which slides, how discrepancies were resolved, and whether diagnoses in the final tables reflect the agreed terms. A silent change of a diagnosis between draft and final without an audit trail is a reconstructability problem under the I.C.3 report expectation.

Recovery groups, local versus systemic, target organs

Recovery (reversibility) arms—OECD Test Guideline 408 often considers extra animals on control and high dose for a treatment-free period—ask whether the finding was transient. Hypertrophy and many hyperplasias reverse. Fibrosis, extensive necrosis with loss of architecture, and neoplasia do not reverse on a four-week recovery. Partial recovery still informs how you talk about human risk; “reversed” is not the same as “never happened.”

Local toxicity occurs at the portal of entry or administration site: nasal epithelium after inhalation, forestomach after an irritant gavage, injection-site myositis. Systemic toxicity requires absorption and a distant organ. A finding can be both (an inhaled cytotoxicant with nasal and liver lesions). Do not list the injection site as a “systemic target organ” solely because myositis is histologically real.

A target organ is identified when the package is coherent: dose-response, more than one related endpoint (weight plus chemistry plus histology), consistency across sex or species as applicable, and not explained by stress or body-weight loss alone. One statistically significant organ-weight blip without histologic or clinical-pathology support is a hypothesis, not a target-organ declaration.

Study report elements (I.C.3) and integration (I.C.4)

Handbook I.C.3 expects a reconstructable report: a narrative (methods, results, discussion, conclusions), summary tables (group means, incidences, severity), and individual animal data. Pathology is usually a signed contributing-scientist report folded into the Study Director’s final report. Omitting individual data so that only starred means remain is not a complete safety report. A reviewer must be able to see whether one outlier created the mean, whether a death had a matching lesion, and whether clinical pathology and histology belong to the same animal.

I.C.4 is the integration step. In-life clinical signs, body weight, and food consumption, clinical pathology, organ weights, gross necropsy, histopathology, and toxicokinetics should tell one story. Contradictions get discussed. A high-dose group with hunched posture, 15% body-weight loss, a stress leukogram, thymic involution, and no chemical-specific enzyme pattern may be systemic stress from unpalatability, not a unique immunotoxic target organ—unless recovery, dose-response, and lymphoid functional assays say otherwise.

Statistical versus biological significance. A p-value below 0.05 on a 10% ALT increase still inside the historical-control range, with no histologic correlate, is often not biologically adverse. A non-significant but dose-related six-fold ALT increase in a small NHP study (n = 3/sex) with matching necrosis is biologically important. Multiple-comparison noise is real in wide clinical-pathology batteries; so is underpowered primate histology. Historical controls help you sanity-check; they do not replace concurrent controls.

Walk every contested finding through the same sequence: Is it present versus concurrent controls? Does chemistry agree? What is on the slide? Is it local or systemic? Does it reverse? Then call adversity.

Scenario

High-dose rats lose 12% body weight. Liver absolute weight is unchanged; liver/body weight is statistically increased; brain-relative liver weight is unchanged; ALT is quiet; histology is normal. The cautious call is no liver target-organ effect—the ratio moved because the carcass shrank.

A second study shows centrilobular hypertrophy, induced CYPs, no necrosis, ALT unchanged, and complete reversal after four weeks off-dose. That package supports an adaptive hypertrophy reading, with the hypertrophy still described and tabulated.

A third study has a non-significant six-fold ALT increase in monkeys, matching centrilobular necrosis in two of three high-dose animals, and individual data that make the pattern obvious. Calling it “not significant, therefore not adverse” fails I.C.4.

Traps

• Calling every relative-to-body-weight increase a true organ enlargement.
• Equating hypertrophy with adversity, or equating reversibility with “not a finding.”
• Dropping individual animal listings from the report.
• Letting a p-value override concordant chemistry and necrosis, or letting a p-value create adversity without biology.
• Treating a gavage-site ulcer as proof of systemic gastrointestinal target-organ toxicity without looking at distant gut.